The pharmaceutical company has acquired a 45% stake in Alkahest, which aims to fight diseases using plasma transplants from younger patients.
Alkahest, a US-based biopharmaceutical company working on restoring mental capability in older patients by using blood plasma from younger donors, received $37.5m in funding from pharmaceutical firm Grifols yesterday.
Grifols has obtained a 45% stake with the investment, which was made alongside a further $12.5m to fund Alkahest’s development of plasma-based products to treat cognitive decline.
Plasma makes up just over half the volume of blood and is the fluid in which blood cells float. It contains, among other things,…
